News

Current Focus: Evobiotics

Evobiotics was founded In 2016 with the purpose of discovering and developing novel antimicrobial compounds to treat bacterial & fungal infections in humans.  It is currently supported by seed funding from Acidophil, and is seeking grants in 2019 to fund its research and development efforts. […]

Read More…

AgPitch18 names AgrIMetis as finalist in their top five emerging companies

AgPitch18 Finalist – AgriMetis The world needs a more innovative approach to combining both biology and chemistry to make novel, effective chemical structures that can lower production costs and/or increase food output. It typically takes hundreds of millions of dollars for traditional agricultural chemical companies (ag chem) to discover, develop and deliver one ag chem product. […]

Read More…

CHALANTE TO PRESENT AT AGRI-TECH INVESTMENT SHOWCASE

  Chalante has been selected to present at the World Agri-Tech Innovation Summit in London on the 16th and 17th of October 2018. They are one of six companies chosen to showcase their technology or solution to the audience of global agribusinesses, technology integrators, and VC investors. Chalante’s presentation will be given by Dr. Simon Aspland, General […]

Read More…

CHALANTE TO PRESENT AT ANIMAL HEALTH INVESTMENT FORUM

Chalante has been selected to present at the Animal Health Investment Forum in Kansas City (USA) on August 21st, 2018. They are one of 12 emerging animal health and nutrition companies chosen to present their innovative programs to a panel of industry experts. Chalante’s presentation will be given by Dr. Simon Aspland, General Manager. More […]

Read More…

CHALANTE AWARDED INNOVATE UK GRANT

Chalante has been awarded a Health and Life Sciences Innovate UK grant to fund the initial development of its novel antibiotic-free performance enhancers for efficient growth of food animals. The grant will be managed by Dr Sandra Hogg, the Director of Biology of Chalante. […]

Read More…

CHALANTE TO PRESENT AT ANIMAL HEALTH INNOVATION LATIN AMERICA 2018

Chalante has been selected to present at the Animal Health Innovation Latin America Company Showcase on May 29-30, 2018 in São Paulo, Brazil.  They were chosen as one of the six companies from the US, Europe and other regions that are looking to bring new, innovative products to the Latin American market. Chalante’s presentation will be […]

Read More…

Monsanto and AgriMetis Announce Global Licensing Agreement to Drive Novel Insect Control Solutions

ST. LOUIS, Mo. and LUTHERVILLE, Md. (MARCH 21, 2018) – Monsanto Company (NYSE: MON) and AgriMetis, LLC have announced an exclusive collaboration for Monsanto’s continued research with AgriMetis’ SpinoMetis™ platform, which includes novel insect protection compounds derived from a naturally-occurring bacterium. The SpinoMetis platform builds on the established safety and efficacy profiles of other products […]

Read More…

Chalante Launches New Website

Acidophil is excited to announce the launch of a brand-new website for its current focus, Chalante LTD. Visit www.chalante.com to meet the Chalante team and learn about their innovative products in the animal health industry. Questions? Get in touch with someone at Chalante by using their website contact form at www.chalante.com/contact.  […]

Read More…

Chalante to present at Animal Health Investment Europe 2018

Chalante is one of the twelve companies selected to present at the Animal Health Investment Europe Emerging Company Showcase on Tuesday 20th of February 2018. More information is available on the 2018 Animal Health Investment Europe webpage: https://www.animalhealthevent.com/events/animal-health-innovation-europe […]

Read More…

PGT SELLS PART OF ITS PATENT PORTFOLIO TO AGILENT

Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population Genetics”). Founded in 2005, Population Genetics was formed to commercialize the intellectual property portfolio of Nobel Laureate Sydney Brenner focused on high sensitivity and high specificity Next Generation Sequencing (“NGS”) detection. In 2015, Population Genetics became an IP holding entity with over 30 patents. Financial terms of the purchase were not disclosed. […]

Read More…